MK-1220

• Description:

  MK-1220 is a covalently reversible inhibitor of the hepatitis C virus (HCV) NS3/4A protease (NS3/4A protease) with a Ki of 0.02 nM. MK-1220 in cell models simulating viral replication exhibits EC50s of 4 (with 10% fetal bovine serum) and 11 nM (50% normal human serum) . MK-1220 can be used for the study of chronic hepatitis C virus infection[1].

• UNSPSC:

  12352005

• Target:

  HBV; HCV Protease

• Related Pathways:

  Anti-infection; Metabolic Enzyme/Protease

• Field of Research:

  Infection

• Smiles:

  CC(C)(COC(N[C@@H](C1CCCCC1)C(N2[C@H](C(N[C@@](C3)(C(NS(=O)(C4CC4)=O)=O)[C@@H]3C=C)=O)C[C@@H](O5)C2)=O)=O)CCCC6=C(OC)C=C7C(C5=NC=C7)=C6

• Molecular Formula:

  C40H53N5O9S

• Molecular Weight:

  779.94

• References & Citations:

  [1]Rudd MT, et al. Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma Exposure. ACS Med Chem Lett. 2011 Jan 12;2 (3) :207-12.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  924270-31-5